Clinical Trial Update: Study of Normal Conditions of Use, Dosing, and Safety of Intravenous (IV) Administration of Vernakalant (MK-6621-049)

View source ↗

Summary

Clinical trial update on vernakalant (MK-6621-049) evaluating normal use, dosing, and IV safety in atrial fibrillation; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Snippet

Sponsor: Correvio International Sarl | Conditions: Atrial Fibrillation | Status: COMPLETED | Results posted: 2019-12-30